National
Mormons, religious groups file brief in support of Prop 8
Brief says supporters’ religious views shouldn’t invalidate measure
The participation of the Church of Latter-Day Saints in a legal brief filed by religious groups in favor of California’s Proposition 8 is vexing an organization that advocates for LGBT Mormons.
In a 38-page friend-of-the-court brief, filed before the Supreme Court Jan. 29, religious groups — including the Mormon Church — emphasize that justices shouldn’t strike down Prop 8 on the basis of religious support for the anti-gay amendment. The brief is signed by Von Keech, a Utah-based private attorney who has previously assisted the Mormon Church, as well as other private attorneys with his firm Alexander Dushku, R. Shawn Gunnarson and Kirton McConkie.
“[O]ur members supported Proposition 8 based on sincere beliefs in the value of traditional marriage for children, families, society, and our republican form of government,” the brief states. “Only a demeaning view of religion and religious believers could dismiss our advocacy of Proposition 8 as ignorance, prejudice, or animus.”
In a statement on Monday, Affirmation, a national group for gay and lesbian Mormons, questioned why the Mormon Church would participate in a legal brief in favor of Prop 8 after backing off its support of anti-gay measures since the passage of the California’s constitutional ban on same-sex marriage in 2008.
“I agree that churches should have the freedom to petition the government and that Proposition 8 should not be invalidated due to religious support of the initiative,” said Affirmation President Randall Thacker, who’s gay. “However, we believe Proposition 8 should be invalidated on the grounds that it denies protections to same-sex couples who have committed to care and provide for each other and their children, a grouping that is clearly defined as a family by the majority of society.”
Spencer Clark, who’s straight and president of Mormons for Marriage Equality, said he agrees the law should provide a foundation for strong families, but said Prop 8 harms children being raised by same-sex parents.
“Unfortunately, Proposition 8 provides no additional benefits to straight couples while denying substantial benefits and legitimacy to gay and lesbian couples who are also raising children,” Clark said. “The brief argues for a conception of marriage that blatantly ignores the hundreds of thousands of children in the United States being raised by same-sex couples, pretending that these loving families don’t exist.”
In 2008, the Church of Jesus Christ of Latter-Day Saints was among the strongest advocates of Prop 8 when it came before California voters as a ballot measure. The church called on members to become involved with the campaign, who contributed as much as half of the $40 million raised and consisted of up to 90 percent of the initial volunteer force to support the ballot measure.
But many observers believe the passage of Prop 8 resulted in a negative press for the Mormon Church. Since that time, the church hasn’t been as involved in ballot initiatives involving marriage, came out in support of an non-discrimination ordinance in Salt Lake City, and launched a website called MormonsAndGays.org to encourage gay members to stay within the church.
A spokesperson for the Mormon Church in Salt Lake City said she couldn’t respond in time for Blade deadline on why the church was participating in a legal brief after adopting a more pro-LGBT tone.
Other groups whose names are on the brief are the National Association of Evangelicals, the Ethics & Religious Liberty Commission of the Southern Baptist Convention; the Lutheran Church-Missouri Synod; the Union of Orthodox Jewish Congregations of America; the Romanian-American Evangelical Alliance of North America; and Truth in Action Ministries.
The brief offers three major reasons for why the Supreme Court should uphold Prop 8, which the court is currently reviewing as result of pending litigation known as Hollingsworth v. Perry: 1) Prop 8 reflects a rational choice amid conflicting views of marriage, not prejudice; 2) Prop 8 should not be invalid because it expresses the views of religious voters; 3) Prop 8 is in line with the values of California voters and more likely to sustain the institute of marriage.
“Proposition 8 expresses the people’s sense that society should continue preserving marriage as the institutional bond joining together and protecting a husband, a wife, and their children,” the brief states. “That complex judgment was no doubt influenced by traditional marriage’s roots in California’s history, culture, laws, and diverse religions and by the public goods the people understand it provides in erecting an orderly social mechanism to cope with natural reproduction … and in protecting the family setting where children thrive best … and best acquire the ‘moral powers requisite for politically liberal citizenship.'”
The brief concludes: “The people of California violated no one’s civil rights when they adopted Proposition 8. Their twice- expressed preference for the traditional definition of marriage over an untested rival conception was thoroughly rational. It is therefore thoroughly constitutional.”
The same religious groups — including the Mormon Church — also filed a 22-page friend-of-the-court brief before the Supreme Court in favor of the Defense of Marriage Act. Similar to the Prop 8 brief, the DOMA brief contends the anti-gay federal law shouldn’t be made invalid because of the moral and religious views voiced in support of it. The brief is signed by Von Keetch and the same other attorneys who signed the Prop 8 brief.
A Wider Bridge on Friday announced it will shut down at the end of the month.
The group that “mobilizes the LGBTQ community to fight antisemitism and support Israel and its LGBTQ community” in a letter to supporters said financial challenges prompted the decision.
“After 15 years of building bridges between LGBTQ communities in North America and Israel, A Wider Bridge has made the difficult decision to wind down operations as of Dec. 31, 2025,” it reads.
“This decision comes after challenging financial realities despite our best efforts to secure sustainable funding. We deeply appreciate our supporters and partners who made this work possible.”
Arthur Slepian founded A Wider Bridge in 2010.
The organization in 2016 organized a reception at the National LGBTQ Task Force’s Creating Change Conference in Chicago that was to have featured to Israeli activists. More than 200 people who protested against A Wider Bridge forced the event’s cancellation.
A Wider Bridge in 2024 urged the Capital Pride Alliance and other Pride organizers to ensure Jewish people can safely participate in their events in response to an increase in antisemitic attacks after Hamas militants attacked Israel on Oct. 7, 2023.
The Jewish Telegraphic Agency reported authorities in Vermont late last year charged Ethan Felson, who was A Wider Bridge’s then-executive director, with lewd and lascivious conduct after alleged sexual misconduct against a museum employee. Rabbi Denise Eger succeeded Felson as A Wider Bridge’s interim executive director.
A Wider Bridge in June honored U.S. Rep. Debbie Wasserman Schultz (D-Fla.) at its Pride event that took place at the Capital Jewish Museum in D.C. The event took place 15 days after a gunman killed two Israeli Embassy employees — Yaron Lischinsky and Sarah Milgrim — as they were leaving an event at the museum.
“Though we are winding down, this is not a time to back down. We recognize the deep importance of our mission and work amid attacks on Jewish people and LGBTQ people – and LGBTQ Jews at the intersection,” said A Wider Bridge in its letter. “Our board members remain committed to showing up in their individual capacities to represent queer Jews across diverse spaces — and we know our partners and supporters will continue to do the same.”
Editor’s note: Washington Blade International News Editor Michael K. Lavers traveled to Israel and Palestine with A Wider Bridge in 2016.
The White House
‘Trump Rx’ plan includes sharp cuts to HIV drug prices
President made announcement on Friday
President Donald Trump met with leaders from some of the world’s largest pharmaceutical companies at the White House on Friday to announce his new “Trump Rx” plan and outline efforts to reduce medication costs for Americans.
During the roughly 47-minute meeting in the Roosevelt Room, Trump detailed his administration’s efforts to cut prescription drug prices and make medications more affordable for U.S. patients.
“Starting next year, American drug prices will come down fast, furious, and will soon be among the lowest in the developed world,” Trump said during the meeting. “For decades, Americans have been forced to pay the highest prices in the world for prescription drugs by far … We will get the lowest price of anyone in the world.”
Trump signed an executive order in May directing his administration “to do everything in its power to slash prescription drug prices for Americans while getting other countries to pay more.”
“This represents the greatest victory for patient affordability in the history of American health care, by far, and every single American will benefit,” he added.
Several pharmaceutical executives stood behind the president during the announcement, including Sanofi CEO Paul Hudson, Novartis CEO Vas Narasimhan, Genentech CEO Ashley Magargee, Boehringer Ingelheim (USA) CEO Jean-Michel Boers, Gilead Sciences CEO Dan O’Day, Bristol Myers Squibb General Counsel Cari Gallman, GSK CEO Emma Walmsley, Merck CEO Robert Davis, and Amgen Executive Vice President Peter Griffith.
Also in attendance were Health and Human Services Secretary Robert F. Kennedy Jr., Commerce Secretary Howard Lutnick, Centers for Medicare and Medicaid Services Administrator Mehmet Oz, and Food and Drug Administration Commissioner Marty Makary.
Under the Trump Rx plan, the administration outlined a series of proposed drug price changes across multiple companies and therapeutic areas. Among them were reductions for Amgen’s cholesterol-lowering drug repatha from $573 to $239; Bristol Myers Squibb’s HIV medication reyataz from $1,449 to $217; Boehringer Ingelheim’s type 2 diabetes medication jentadueto from $525 to $55; Genentech’s flu medication xofluza from $168 to $50; and Gilead Sciences’ hepatitis C medication epclusa from $24,920 to $2,425.
Additional reductions included several GSK inhalers — such as the asthma inhaler advair diskus 500/50, from $265 to $89 — Merck’s diabetes medication januvia from $330 to $100, Novartis’ multiple sclerosis medication mayzent from $9,987 to $1,137, and Sanofi’s blood thinner plavix from $756 to $16. Sanofi insulin products would also be capped at $35 per month’s supply.
These prices, however, would only be available to patients who purchase medications directly through TrumpRx. According to the program’s website, TrumpRx “connects patients directly with the best prices, increasing transparency, and cutting out costly third-party markups.”
Kennedy spoke after Trump, thanking the president for efforts to lower pharmaceutical costs in the U.S., where evidence has shown that drug prices — including both brand-name and generic medications — are nearly 2.78 times higher than prices in comparable countries. According to the Pharmaceutical Research and Manufacturers of America, roughly half of every dollar spent on brand-name drugs goes to entities that play no role in their research, development, or manufacturing.
“This is affordability in action,” Kennedy said. “We are reversing that trend and making sure that Americans can afford to get the life-saving solutions.”
Gilead CEO Dan O’Day also spoke about how the restructuring of drug costs under TrumpRx, combined with emerging technologies, could help reduce HIV transmission — a virus that, if untreated, can progress to AIDS. The LGBTQ community remains disproportionately affected by HIV.
“Thank you, Mr. President — you and the administration,” O’Day said. “I think this objective of achieving the commitment to affordability and future innovation is extraordinary … We just recently launched a new medicine that’s only given twice a year to prevent HIV, and we’re working with Secretary Kennedy and his entire team, as well as the State Department, as a part of your strategy to support ending the epidemic during your term.
“I’ve never been more optimistic about the innovation that exists across these companies and the impact this could have on America’s health and economy,” he added.
Trump interjected, asking, “And that’s working well with HIV?”
“Yes,” O’Day replied.
“It’s a big event,” Trump said.
“It literally prevents HIV almost 100 percent given twice a year,” O’Day responded.
A similar anti-HIV medication is currently prescribed more than injectable form mentioned by O’Day. PrEP, is a medication regimen proven to significantly reduce HIV infection rates for people at high risk. Without insurance, brand-name Truvada can cost roughly $2,000 per month, while a generic version costs about $60 per month.
Even when medication prices are reduced, PrEP access carries additional costs, including clinic and laboratory fees, office visits, required HIV and sexually transmitted infection testing, adherence services and counseling, and outreach to potentially eligible patients and providers.
According to a 2022 study, the annual total cost per person for PrEP — including medication and required clinical and laboratory monitoring — is approximately $12,000 to $13,000 per year.
The TrumpRx federal platform website is now live at TrumpRx.gov, but the program is not slated to begin offering reduced drug prices until January.
The White House
EXCLUSIVE: Democracy Forward files FOIA lawsuit after HHS deadnames Rachel Levine
Trans former assistant health secretary’s name changed on official portrait
Democracy Forward, a national legal organization that works to advance democracy and social progress through litigation, policy and public education, and regulatory engagement, filed a lawsuit Friday in federal court seeking to compel the U.S. Department of Health and Human Services to release information related to the alteration of former Assistant Secretary for Health Adm. Rachel Levine’s official portrait caption.
The lawsuit comes in response to the slow pace of HHS’s handling of multiple Freedom of Information Act requests — requests that federal law requires agencies to respond to within 20 working days. While responses can take longer due to backlogs, high request volumes, or the need for extensive searches or consultations, Democracy Forward says HHS has failed to provide any substantive response.
Democracy Forward’s four unanswered FOIA requests, and the subsequent lawsuit against HHS, come days after someone in the Trump-Vance administration changed Levine’s official portrait in the Hubert H. Humphrey Building to display her deadname — the name she used before transitioning and has not used since 2011.
According to Democracy Forward, HHS “refused to release any records related to its morally wrong and offensive effort to alter former Assistant Secretary for Health Admiral Rachel Levine’s official portrait caption.” Levine was the highest-ranking openly transgender government official in U.S. history and served as assistant secretary for health and as an admiral in the U.S. Public Health Service Commissioned Corps from 2021 to 2025.
Democracy Forward President Skye Perryman spoke about the need to hold the Trump-Vance administration accountable for every official action, especially those that harm some of the most targeted Americans, including trans people.
“The question every American should be asking remains: what is the Trump-Vance administration hiding? For an administration that touts its anti-transgender animus and behavior so publicly, its stonewalling and silence when it comes to the people’s right to see public records about who was behind this decision is deafening,” Perryman said.
“The government’s obligation of transparency doesn’t disappear because the information sought relates to a trailblazing former federal official who is transgender. It’s not complicated — the public is entitled to know who is making decisions — especially decisions that seek to alter facts and reality, erase the identity of a person, and affect the nation’s commitment to civil rights and human dignity.”
“HHS’s refusal to respond to these lawful requests raises more serious concerns about transparency and accountability,” Perryman added. “The public has every right to demand answers — to know who is behind this hateful act — and we are going to court to get them.”
The lawsuit also raises questions about whether the alteration violated federal accuracy and privacy requirements governing Levine’s name, and whether the agency improperly classified the change as an “excepted activity” during a lapse in appropriations. By failing to make any determination or produce any records, Democracy Forward argues, HHS has violated its obligations under federal law.
The case, Democracy Forward Foundation v. U.S. Department of Health and Human Services, was filed in the U.S. District Court for the District of Columbia. The legal team includes Anisha Hindocha, Daniel McGrath, and Robin Thurston.
The Washington Blade reached out to HHS, but has not received any comment.
The lawsuit and four FOIA requests are below:

